Roberts Glore & CO Inc Neurocrine Biosciences Inc Transaction History
Roberts Glore & CO Inc
- $328 Million
- Q2 2024
A detailed history of Roberts Glore & CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Roberts Glore & CO Inc holds 1,492 shares of NBIX stock, worth $189,737. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,492
Previous 1,492
-0.0%
Holding current value
$189,737
Previous $205,000
-0.0%
% of portfolio
0.06%
Previous 0.06%
Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
617Shares Held
94.7MCall Options Held
583KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.8 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.28 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$586 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$314 Million0.6% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.9MShares$241 Million4.37% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...